A preliminary retrospective analysis of weekly topotecan in recurrent small-cell lung cancer.

@article{Kasturi2004APR,
  title={A preliminary retrospective analysis of weekly topotecan in recurrent small-cell lung cancer.},
  author={V K Kasturi and John R. Eckardt and Frank Anthony Greco},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={7359}
}
7359 Background: Topotecan 1.5 mg/m2 administered IV on days 1 - 5 of a 21-day cycle is a standard regimen in recurrent small-cell lung cancer (SCLC). Topotecan administered weekly may offer improved tolerability in this patient (pt) population. METHODS We are performing a retrospective study to investigate the tolerability and potential treatment benefit of weekly topotecan in pts with recurrent SCLC. Records from pts treated with weekly topotecan after failure of first-line therapy with… CONTINUE READING